Related Experiment Video

Updated: Jun 24, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Experiences with the use of caspofungin in paediatric patients

Thomas Lehrnbecher1, Andreas H Groll

  • 1Pediatric Hematology, University Children's Hospital, Frankfurt am Main, Germany. thomas.lehrnbecher@kgu.de

Mycoses
|May 28, 2008
PubMed

Insights

New antifungal echinocandin lipopeptides like caspofungin are crucial for treating invasive fungal infections in immunocompromised children and neonates. This review covers its use in these vulnerable populations.

Area of Science:

  • Medical research
  • Pharmacology
  • Paediatric medicine

Background:

  • Invasive fungal infections pose significant risks for immunocompromised children, including those with hematological malignancies and undergoing stem cell transplantation.
  • Neonates, especially preterm infants, are also highly susceptible to invasive mycoses.
  • Recent advancements have expanded the arsenal of antifungal drugs.

Purpose of the Study:

  • To review the clinical pharmacology of caspofungin.
  • To summarize published data on caspofungin use in neonates and immunocompromised children.

Main Methods:

  • Literature review of clinical pharmacology and published experience with caspofungin.
  • Focus on paediatric and neonatal populations.

Main Results:

  • Caspofungin represents a novel echinocandin lipopeptide class of antifungals.
  • Despite not being universally licensed for paediatric use, its prescription in children is increasing.
  • Published data on its use in neonates and immunocompromised children is being gathered.

Conclusions:

  • Caspofungin shows promise as a treatment option for invasive fungal infections in paediatric patients.
  • Further research and data are needed to fully establish its role and safety in neonates and immunocompromised children.

More Related Videos

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...